{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:18:53Z","timestamp":1780568333523,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T00:00:00Z","timestamp":1439856000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001254","name":"Ipsen Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001254","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s00345-015-1666-5","type":"journal-article","created":{"date-parts":[[2015,8,17]],"date-time":"2015-08-17T10:59:23Z","timestamp":1439809163000},"page":"755-761","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750\u00a0U for treating neurological detrusor overactivity"],"prefix":"10.1007","volume":"34","author":[{"given":"Benoit","family":"Peyronnet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Roumigui\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Castel-Lacanal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Guillotreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Marque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Rischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Gam\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,18]]},"reference":[{"key":"1666_CR1","unstructured":"Pannek J, Blok B, Castro-Diaz D et al (2014) EAU guidelines on neuro-urology. http:\/\/www.uroweb.org\/gs\/pdf\/21%20Neuro-Urology_LR.p"},{"key":"1666_CR2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJM200003023420918","volume":"342","author":"B Schurch","year":"2000","unstructured":"Schurch B, Schmid DM, Stohrer M (2000) Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 342:665","journal-title":"N Engl J Med"},{"key":"1666_CR3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","volume":"55","author":"A Apostolidis","year":"2009","unstructured":"Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A et al (2009) Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 55:100\u2013119","journal-title":"Eur Urol"},{"key":"1666_CR4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","volume":"174","author":"B Schurch","year":"2005","unstructured":"Schurch B, de Seze M, Denys P et al (2005) Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174:196\u2013200","journal-title":"J Urol"},{"key":"1666_CR5","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.juro.2011.02.004","volume":"185","author":"S Herschorn","year":"2011","unstructured":"Herschorn S, Gajewski J, Ethans K et al (2011) Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol 185:2229\u20132235","journal-title":"J Urol"},{"key":"1666_CR6","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","volume":"187","author":"D Ginsberg","year":"2012","unstructured":"Ginsberg D, Gousse A, Keppenne V et al (2012) Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 187:2131\u20132139","journal-title":"J Urol"},{"key":"1666_CR7","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","volume":"60","author":"F Cruz","year":"2011","unstructured":"Cruz F, Herschorn S, Aliotta P et al (2011) Efficacy and safety of onabotulinumtoxin A in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 60:742\u2013750","journal-title":"Eur Urol"},{"key":"1666_CR8","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1002\/nau.22630","volume":"33","author":"F Cruz","year":"2014","unstructured":"Cruz F, Nitti V (2014) Chapter 5: clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB). Neurourol Urodyn 33:S26\u2013S31","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"1666_CR9","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.eururo.2004.11.009","volume":"47","author":"J Grosse","year":"2005","unstructured":"Grosse J, Kramer G, St\u00f6hrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47(5):653\u2013659","journal-title":"Eur Urol"},{"issue":"4","key":"1666_CR10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/nau.20403","volume":"26","author":"IF Ghalayini","year":"2007","unstructured":"Ghalayini IF, Al-Ghazo MA (2007) Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction. Neurourol Urodyn 26(4):531\u2013536","journal-title":"Neurourol Urodyn"},{"key":"1666_CR11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/00365590601068835","volume":"41","author":"I Ehren","year":"2007","unstructured":"Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C et al (2007) Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 41:335\u2013340","journal-title":"Scand J Urol Nephrol"},{"key":"1666_CR12","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.eururo.2007.09.034","volume":"53","author":"G Popolo Del","year":"2008","unstructured":"Del Popolo G, Filocamo MT, Li Marzi V, Macchiarella A, Cecconi F, Lombardi G et al (2008) Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre. Eur Urol 53:1013\u20131019","journal-title":"Eur Urol"},{"key":"1666_CR13","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1464-410X.2006.06091.x","volume":"97","author":"A Ruffion","year":"2006","unstructured":"Ruffion A, Capelle O, Paparel P, Leriche B, Leriche A, Grise P (2006) What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 97:1030\u20131034","journal-title":"BJU Int"},{"key":"1666_CR14","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.eururo.2010.06.035","volume":"58","author":"P Grise","year":"2010","unstructured":"Grise P, Ruffion A, Denys P, Egon G, Chartier Kastler E (2010) Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses. Eur Urol 58:759\u2013766","journal-title":"Eur Urol"},{"key":"1666_CR15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205\u2013213","journal-title":"Ann Surg"},{"key":"1666_CR16","unstructured":"Peyronnet B, Roumigui\u00e9 M, Castel-Lacanal E et al (2014) Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity. Neurourol Urodyn. doi:10.1002"},{"key":"1666_CR17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1464-410X.2006.06192.x","volume":"98","author":"PS Patki","year":"2006","unstructured":"Patki PS, Hamid R, Arumugam K, Shah PJ, Craggs M (2006) Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int 98:77\u201382","journal-title":"BJU Int"},{"key":"1666_CR18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s11255-009-9528-y","volume":"41","author":"IF Ghalayini","year":"2009","unstructured":"Ghalayini IF, Al-Ghazo MA, Elnasser ZA (2009) Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity. Int Urol Nephrol 41:805\u2013813","journal-title":"Int Urol Nephrol"},{"key":"1666_CR19","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1464-410X.2009.08466.x","volume":"104","author":"J Grosse","year":"2009","unstructured":"Grosse J, Kramer G, Jakse G (2009) Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case\u2013control study. BJU Int 104:651\u2013656","journal-title":"BJU Int"},{"key":"1666_CR20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.urology.2005.06.116","volume":"66","author":"FJ Bianco Jr","year":"2005","unstructured":"Bianco FJ Jr, Scardino PT, Eastham JA (2005) Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (\u201ctrifecta\u201d). Urology 66:83\u201394","journal-title":"Urology"},{"issue":"1","key":"1666_CR21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.juro.2012.09.042","volume":"189","author":"AJ Hung","year":"2013","unstructured":"Hung AJ, Cai J, Simmons MN, Gill IS (2013) Trifecta in partial nephrectomy. J Urol 189(1):36\u201342","journal-title":"J Urol"},{"key":"1666_CR22","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/j.1464-410X.2007.07186.x","volume":"100","author":"S Jeffery","year":"2007","unstructured":"Jeffery S, Fynes M, Lee F, Wang K, Williams L, Morley R (2007) Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 100:1302\u20131306","journal-title":"BJU Int"},{"key":"1666_CR23","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/j.1464-410X.2010.09435.x","volume":"106","author":"S Mouttalib","year":"2010","unstructured":"Mouttalib S, Khan S, Castel-Lacanal E, Guillotreau J, De Boissezon X, Malavaud B et al (2010) Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment. BJU Int 106:1677\u20131680","journal-title":"BJU Int"},{"key":"1666_CR24","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0022-5347(05)67157-1","volume":"164","author":"A Esclarin Ruz De","year":"2000","unstructured":"De Esclarin Ruz A, Garcia Leoni E, Herruzo Cabrera R (2000) Epidemiology and risk factors for urinary tract infection in patients with spinal cord injury. J Urol 164:1285\u20131289","journal-title":"J Urol"},{"key":"1666_CR25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WNF.0b013e3181914d0a","volume":"32","author":"O Lange","year":"2009","unstructured":"Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K (2009) Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 32:213\u2013218","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"1666_CR26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.urology.2012.11.010","volume":"81","author":"M Kennelly","year":"2013","unstructured":"Kennelly M, Dmochowski R, Ethans K, Karsenty G, Schulte-Baukloh H, Jenkins B, Thompson C et al (2013) Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis. Urology 81(3):491\u2013497","journal-title":"Urology"},{"issue":"9","key":"1666_CR27","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/j.1464-410X.2009.08600.x","volume":"104","author":"J Pannek","year":"2009","unstructured":"Pannek J, G\u00f6cking K, Bersch U (2009) Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. BJU Int 104(9):1246\u20131250","journal-title":"BJU Int"},{"issue":"2","key":"1666_CR28","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11599840-000000000-00000","volume":"26","author":"R Benecke","year":"2012","unstructured":"Benecke R (2012) Clinical relevance of botulinum toxin immunogenicity. BioDrugs. 26(2):e1\u2013e9","journal-title":"BioDrugs."},{"key":"1666_CR29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1442-2042.2008.02016.x","volume":"15","author":"H Schulte-Baukloh","year":"2008","unstructured":"Schulte-Baukloh H, Bigalke H, Miller K et al (2008) Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure. Int J Urol 15:407\u2013415","journal-title":"Int J Urol"},{"key":"1666_CR30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.annrmp.2008.03.003","volume":"51","author":"M Seze de","year":"2008","unstructured":"de Seze M, Ruffion A, Haab F, Chartier-Kastler E, Denys P, Game X et al (2008) Suivi des patients apr\u00e8s injection de toxine botulique intrad\u00e9trusorienne Recommandations de bonne pratique clinique chez le patient neurologique. Ann Readapt Med Phys 51:315\u2013321","journal-title":"Ann Readapt Med Phys"},{"key":"1666_CR31","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","volume":"60","author":"A Mangera","year":"2011","unstructured":"Mangera A, Andersson KE, Apostolidis A et al (2011) Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 60:784\u2013795","journal-title":"Eur Urol"},{"issue":"1","key":"1666_CR32","doi-asserted-by":"crossref","first-page":"27.e1-4","DOI":"10.1016\/j.jpurol.2014.08.009","volume":"11","author":"S Tiryaki","year":"2015","unstructured":"Tiryaki S, Yagmur I, Parlar Y et al (2015) Botulinum injection is useless on fibrotic neuropathic bladders. J Pediatr Urol 11(1):27.e1-4","journal-title":"J Pediatr Urol"},{"issue":"8","key":"1666_CR33","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/nau.21124","volume":"30","author":"M Horst","year":"2011","unstructured":"Horst M, Weber DM, Bodmer C, Gobet R (2011) Repeated Botulinum-A toxin injection in the treatment of neuropathic bladder dysfunction and poor bladder compliance in children with myelomeningocele. Neurourol Urodyn 30(8):1546\u20131549","journal-title":"Neurourol Urodyn"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-015-1666-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-015-1666-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-015-1666-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:40:23Z","timestamp":1559036423000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-015-1666-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,18]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["1666"],"URL":"https:\/\/doi.org\/10.1007\/s00345-015-1666-5","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,18]]}}}